ReviewHypertension research : official journal of the Japanese Society of Hypertension2025
The relationship between estrogen and renin angiotensin system components in the context of hypertension.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- The double-edged sword effect of estrogen in kidney disease and its precision modulation.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is recognized as a significant risk factor for the development of cardiovascular diseases (CVD), stroke, and kidney diseases. Although hypertension is influenced by numerous factors, the renin-angiotensin system (RAS) is widely acknowledged as a critical regulator of normal blood pressure (BP) stability and a significant contributor to the development of hypertension. RAS has different peptides and receptors that exert their effects via two alternative and classical pathways. In females, estradiol exhibits protective effects on the cardiovascular and renal systems. It may modulate BP regulation via its influence on the RAS, affecting the levels of crucial substrates, enzymes, receptor expression, and protein production. Sex disparities in hypertension are apparent in various hypertensive animal models. This review explored the connection between estrogen and RAS components in the context of hypertension.
Indexed as
Identifiers
41094182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.